The effect of pH on the buccal and sublingual absorption of captopril
- PMID: 8641325
- DOI: 10.1007/BF00194953
The effect of pH on the buccal and sublingual absorption of captopril
Abstract
The effect of pH on the buccal and sublingual absorption of captopril was evaluated using in vitro techniques and human studies. Partitioning of captopril into n-octanol was lowest over the pH range 5 to 8 and highest at pH values 3, 4 and 9. Using the buccal absorption technique, the partitioning of captopril (2 mg) was examined in six healthy male volunteers from buffered solutions (pH 3, 4, 5, 6, 7, 8, and 9). Lowest buccal partitioning occurred at pH 3 while maximal buccal partitioning occurred at pH 7. These data clearly indicated that the buccal absorption of captopril pharmacokinetic and pharmacodynamic parameters were determined after administration of buffered sublingual captopril (pH 7, optimal hP for absorption as determined from the buccal partitioning data) and unbuffered sublingual captopril. The study was performed in eight healthy volunteers in a randomised single-blind cross-over fashion. The tmax for captopril was found to be approximately 11 minutes earlier after buffered versus unbuffered sublingual administration and AUC0-30 min increased by approximately 30% in the case of buffered captopril. Cpmas, AUC0-180 min and relative bioavailability did not differ between the buffered and unbuffered administration. Pharmacodynamic parameters (BP, heart rate and plasma renin activity) did not differ significantly between buffered and unbuffered sublingual administration. The increased rate of captopril absorption after buffered sublingual administration was small and is likely to offer little therapeutic advantage over conventional sublingual formulation.
Similar articles
-
A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.Eur J Clin Pharmacol. 1996;49(6):471-6. doi: 10.1007/BF00195933. Eur J Clin Pharmacol. 1996. PMID: 8706772 Clinical Trial.
-
Buccal absorption of enalapril and lisinopril.Eur J Clin Pharmacol. 1998 Oct;54(8):609-14. doi: 10.1007/s002280050522. Eur J Clin Pharmacol. 1998. PMID: 9860147 Clinical Trial.
-
Characterization of captopril sublingual permeation: determination of preferred routes and mechanisms.J Pharm Sci. 2001 Nov;90(11):1868-77. doi: 10.1002/jps.1136. J Pharm Sci. 2001. PMID: 11745744
-
Recent developments in buccal and sublingual delivery systems.Expert Opin Drug Deliv. 2012 Jun;9(6):615-28. doi: 10.1517/17425247.2012.676040. Epub 2012 Apr 19. Expert Opin Drug Deliv. 2012. PMID: 22512476 Review.
-
Microenvironmental pH Modification in Buccal/Sublingual Dosage Forms for Systemic Drug Delivery.Pharmaceutics. 2023 Feb 14;15(2):637. doi: 10.3390/pharmaceutics15020637. Pharmaceutics. 2023. PMID: 36839959 Free PMC article. Review.
Cited by
-
Experimental and Molecular Modeling Studies on the Complexation of Chromium(III) with the Angiotensin-Converting Enzyme Inhibitor Captopril.ACS Omega. 2022 Apr 28;7(18):15909-15918. doi: 10.1021/acsomega.2c00986. eCollection 2022 May 10. ACS Omega. 2022. PMID: 35571803 Free PMC article.
-
Formulation and in vitro evaluation of a fast-disintegrating/sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises.Res Pharm Sci. 2016 Jul;11(4):274-83. doi: 10.4103/1735-5362.189284. Res Pharm Sci. 2016. PMID: 27651807 Free PMC article.
-
A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.Eur J Clin Pharmacol. 1996;49(6):471-6. doi: 10.1007/BF00195933. Eur J Clin Pharmacol. 1996. PMID: 8706772 Clinical Trial.
-
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.Clin Pharmacokinet. 2002;41(9):661-80. doi: 10.2165/00003088-200241090-00003. Clin Pharmacokinet. 2002. PMID: 12126458 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous